{"brief_title": "A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers", "brief_summary": "The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: - Comparison of total helper and suppressor T-cell number between the groups. - Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups. - Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Inosine pranobex"], "criteria": "Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Opportunistic infections or Kaposi's sarcoma. - Critical illness. - History of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer. Concurrent Medication: Excluded: - Steroids. - Cytotoxic immunosuppressive agents. Concurrent Treatment: Excluded: - Radiotherapy. The following are excluded: - Opportunistic infections or Kaposi's sarcoma. - Critically ill patients. - Patients receiving steroids, cytotoxic immunosuppressive agents, and/or radiotherapy. - Patients who have received any other immunotherapy. - Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer. Prior Medication: Excluded: - Any other immunotherapy. Patients who fall into the group which is at risk of developing cutaneous sarcoma and/or opportunistic diseases but at present have no signs or symptoms of these diseases.", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "AIDS-Related Complex", "mesh_term": ["HIV Infections", "Inosine Pranobex"], "id": "NCT00002059"}